Press Releases

Press Releases

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

Aug 15, 2023 | Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

Jun 14, 2023 | Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

The American Thoracic Society Foundation and the American Lung Association announced today that they are co-funding an $80,000 grant that will support important research into the mechanisms underlying Hermansky-Pudlak syndrome (HPS), a rare inherited disease which affects a number of organs including the lungs.

The U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced the launch of a joint initiative to share information on inspections of bioequivalence studies submitted in support of generic drug approvals. This collaborative effort provides a mechanism to conduct joint facility inspections for generic drug applications submitted to both agencies.

Rounding out a very successful year, Accreditation for Cardiovascular Excellence (ACE) reports they have reached record-breaking numbers of accreditation applications for cardiac cath labs in 2013. “Accreditation applications have more than doubled since 2012,” said Mary Heisler, RN, BA, ACE Executive Director. “More labs are realizing the importance of accountable metrics and know it’s time to get started on the quality journey with ACE.”

In a time when competition for federal research funding  is tougher than ever before, the University of Kentucky has been awarded one of the largest health grants ever made to the institution: an $11.3 million National Institutes of Health (NIH) grant  supporting research focusing on issues that plague the Commonwealth - the twin scourges of obesity and cardiovascular disease.

The University of Texas Health Science Center at Houston (UTHealth) has been named one of 25 regional stroke centers by the National Institutes of Health (NIH) and the only one in Texas.

A San Diego medical group's disease management program increased patient engagement rates from 28% to 67%, leading to a decline in both hospitalizations and 30-day readmissions for program participants. In recognition of its innovative chronic care program, Sharp Rees-Stealy Medical Centers received the 2013 Doyle Award from MCG (formerly Milliman Care Guidelines), a leading provider of clinical guidelines to payor and provider markets.

More than 2,000 experts in the field of cardiology will join together at this year's three-day American College of Cardiology 46th New York Cardiovascular Symposium from December 13-15 in New York City. The event, which is one of the most prestigious cardiology events in the world, will review and highlight the latest advances in cardiology for 2013 and the next big things to expect in cardiology in 2014.

With increased penalties in effect for hospitals with excessive readmissions for heart attack and heart failure, the American College of Cardiology is launching a program that applies a team approach to keeping patients at home and healthy after discharge.

Medtronic, Inc. (NYSE: MDT), announced today CE Mark (Conformité Européenne) in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its highly flexible 4 Fr multi-electrode Symplicity Spyral™ catheter and Symplicity G3™ radio frequency (RF) generator. 

Despite significant medical advances, there continue to be significant gaps in the health care of the growing number of patients with valvular heart disease. In the USA, the total number of people aged 65 years or older with valvular heart disease will grow to approximately 5.2 million by year 2020, and 6.8 million individuals by the year 2030 1. The Minneapolis Heart Institute Foundation™ (MHIF) has created a scientific program, "Valve Summit 2014: The Science and Delivery of Optimal, Multi-Disciplinary Care," to address the ongoing, complex evolution in the clinical management of patients with valvular heart disease. The conference will be held on April 25th and 26th at the Radisson Blu in downtown Minneapolis.

At the 99th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), December 1-6 in Chicago, Siemens Healthcare (booth #1934, South Building/Lakeside Center at McCormick Place, Hall A) will introduce a new angiography system optimized for broad clinical utilization. Artis one¹ is designed for routine interventions, including revascularizations of peripheral arterial or venous occlusions, functional tests of dialysis shunts in patients with kidney failure, diagnostic angiographies of narrowed coronary arteries, and pacemaker implantations.

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded the 2013 Toshiba America Medical Systems/RSNA Research Seed Grant to Soterios Gyftopolous, M.D. and two 2013 Toshiba America Medical Systems/RSNA Research Resident Grants to Daniel S. Chow, M.D. and H. Benjamin Harvey, M.D., J.D. These grants are made possible by Toshiba America Medical Systems’ support of the RSNA R&E Foundation.

Chosen for nearly one out of every two endovascular abdominal aortic aneurysm (AAA) repairs worldwide, the Endurant II AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate long-term durability and consistent outcomes at three years in a real-world setting.

AstraZeneca and Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Xigduo™ (dapagliflozin and metformin hydrochloride) for adults aged 18 and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their current metformin-based treatment regimen or who are currently being treated with the combination of dapgliflozin and metformin as separate tablets.

The first device of its kind to undergo clinical evaluation in the United States, the Valiant "Mona LSA" branch thoracic stent graft system from Medtronic, Inc. (NYSE: MDT) has demonstrated proof of concept in a first-in-human study being conducted under the U.S. Food and Drug Administration (FDA)'s "Innovation Pathway" early feasibility pilot program, according to data presented today at the 2013 VEITHsymposium(tm).

Sidra Medical and Research Center today announced that Dr. Ziyad M. Hijazi has been appointed Clinical Chief for Pediatrics. In this role, the pioneering and highly experienced clinician will drive the strategic direction of the Department of Pediatrics and integrate research and education priorities into a program of excellent clinical service delivery. He will also hold the position of Chair of Pediatrics at Weill Cornell Medical College – Qatar, Sidra’s partner for medical education.

A new network dedicated to advancing research and therapies for stroke is forming in Chicago thanks to $2 million in grants from the National Institutes of Health (NIH). The Chicago Stroke Trials Consortium is a partnership among Northwestern Medicine®, Ann & Robert H. Lurie Children's Hospital of Chicago, John H. Stroger Jr. Hospital of Cook County, Loyola University Medical Center, Rehabilitation Institute of Chicago, Rush University Medical Center, and University of Chicago Medicine that will build an infrastructure to support clinical trials for stroke prevention, treatment and recovery. Northwestern University will be the regional coordinating center for the consortium and administer the project over the next five years.

Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study, ETC-1002-006, met its primary endpoint, demonstrating that ETC-1002 significantly lowered LDL-C compared to placebo by an average of 32 percent and was well tolerated. The data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas by principal investigator Paul D. Thompson, M.D. Esperion previously announced positive topline results from this study in June 2013.

New research shows that Medtronic, Inc. (NYSE: MDT) pacemakers with enhanced pacing features have the ability to slow the progression of atrial fibrillation (AF) in patients with bradycardia, or a slow heartbeat.

James A. DeWeese, M.D., a pioneer in cardiothoracic and vascular surgery and a former chair of Cardiothoracic Surgery and Vascular Surgery at the University of Rochester Medical Center, died Nov. 14, 2013. He was 88.

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results showing that its investigational fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran in healthy male volunteers. These results, presented today during the American Heart Association's Scientific Sessions 2013, represent the first clinical data involving the compound, which was discovered and developed by the company (ClinicalTrials.gov Identifier: NCT01955720).